Brief: Janux Therapeutics Q2 Basic EPS USD -0.55

Janux Therapeutics

07/08/2025 21:01

Overview

Janux reports Q2 net loss of $33.9 mln, up from $6.0 mln last year

Cash and investments at $996.0 mln, down from $1.03 bln at end of 2024

$10 mln milestone payment from Merck for first patient dosed in collaboration

Outlook

Janux expects updates on JANX007 and JANX008 in H2 2025

Company continues enrollment for JANX007 and JANX008 trials

Company anticipates data presentations in H2 2025

Result Drivers

CLINICAL MILESTONE - $10 mln payment from Merck triggered by first patient dosed in collaboration program

PIPELINE PROGRESS - Ongoing enrollment for JANX007 and JANX008 in Phase 1 trials, with updates expected in H2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$33.86 mln
Q2 Basic EPS
-$0.55
Q2 Operating Expenses
$45.12 mln
Q2 Operating Income
-$45.12 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Janux Therapeutics Inc is $76.00, about 68.2% above its August 6 closing price of $24.18

Press Release: ID:nBwHYPWKa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)